1.26
Schlusskurs vom Vortag:
$1.31
Offen:
$1.24
24-Stunden-Volumen:
519.12K
Relative Volume:
0.84
Marktkapitalisierung:
$131.85M
Einnahmen:
-
Nettoeinkommen (Verlust:
$1.60M
KGV:
42.00
EPS:
0.03
Netto-Cashflow:
$-62.91M
1W Leistung:
-13.70%
1M Leistung:
-24.10%
6M Leistung:
-28.81%
1J Leistung:
-47.93%
Compugen Ltd Stock (CGEN) Company Profile
Vergleichen Sie CGEN mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
CGEN
Compugen Ltd
|
1.26 | 131.85M | 0 | 1.60M | -62.91M | 0.03 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
474.56 | 121.88B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
572.78 | 62.69B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
550.00 | 33.54B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
232.95 | 30.15B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ONC
Beigene Ltd Adr
|
220.54 | 25.69B | 3.81B | -644.79M | -669.77M | -6.24 |
Compugen Ltd Stock (CGEN) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2025-01-13 | Eingeleitet | Oppenheimer | Outperform |
2022-08-05 | Herabstufung | Jefferies | Buy → Hold |
2020-05-26 | Fortgesetzt | JMP Securities | Mkt Outperform |
2020-05-13 | Eingeleitet | Stifel | Buy |
2020-05-07 | Eingeleitet | SVB Leerink | Outperform |
2020-04-22 | Eingeleitet | ROTH Capital | Buy |
2020-03-24 | Eingeleitet | SunTrust | Buy |
2020-01-16 | Eingeleitet | Cantor Fitzgerald | Overweight |
2018-03-29 | Eingeleitet | Oppenheimer | Outperform |
2016-02-01 | Fortgesetzt | Oppenheimer | Outperform |
2015-10-15 | Eingeleitet | FBR Capital | Outperform |
2015-04-23 | Fortgesetzt | Jefferies | Buy |
2015-04-21 | Eingeleitet | Oppenheimer | Outperform |
2014-02-07 | Eingeleitet | MLV & Co | Buy |
2009-12-28 | Bestätigt | Cantor Fitzgerald | Buy |
2009-07-29 | Eingeleitet | Cantor Fitzgerald | Buy |
Alle ansehen
Compugen Ltd Aktie (CGEN) Neueste Nachrichten
Compugen at Needham Conference: Strategic Immuno-Oncology Insights - Investing.com Australia
Compugen at Needham Conference: Strategic Immuno-Oncology Insights By Investing.com - Investing.com UK
Compugen stock touches 52-week low at $1.35 amid market challenges - Investing.com Canada
Compugen stock touches 52-week low at $1.35 amid market challenges By Investing.com - Investing.com South Africa
BeiGene stock slips on trial discontinuation (ONC:NASDAQ) - Seeking Alpha
Compugen at AI Drug Discovery Conference: Strategic Partnerships Drive Progress - Investing.com
Cancer AI Breakthrough: Compugen Takes Center Stage at 3 Elite Healthcare Forums - Stock Titan
Compugen to Participate in Multiple Virtual Investor Conferences in April 2025 - Yahoo Finance
Compugen Ltd. (CGEN): Among the Penny Stocks With Huge Upside Potential According to Analysts - MSN
Compugen Ltd. (NASDAQ:CGEN) Shares Acquired by Connor Clark & Lunn Investment Management Ltd. - Defense World
Reviewing Aligos Therapeutics (NASDAQ:ALGS) and Compugen (NASDAQ:CGEN) - Armenian Reporter
Compugen at Leerink’s Global Healthcare Conference: Strategic Insights By Investing.com - Investing.com South Africa
Compugen at Leerink’s Global Healthcare Conference: Strategic Insights - Investing.com
Oppenheimer & Co. Inc. Raises Stock Position in Compugen Ltd. (NASDAQ:CGEN) - Defense World
Earnings call transcript: Compugen Q4 2024 reveals revenue decline By Investing.com - Investing.com Australia
Compugen Ltd. to Host Earnings Call - ACCESS Newswire
Compugen (NASDAQ:CGEN) Rating Lowered to Hold at StockNews.com - Defense World
Rodman & Renshaw maintains $4 price target on Compugen stock By Investing.com - Investing.com Australia
Compugen Ltd. (NASDAQ:CGEN) Q4 2024 Earnings Call Transcript - Insider Monkey
Compugen Ltd (CGEN) Q4 2024 Earnings Call Highlights: Strategic Advances Amid Financial Challenges - GuruFocus.com
Compugen’s 2024 Results Highlight Clinical Progress and Financial Stability - TipRanks
Earnings call transcript: Compugen Q4 2024 reveals revenue decline - Investing.com India
Rodman & Renshaw maintains $4 price target on Compugen stock - Investing.com India
Compugen Ltd reports results for the quarter ended December 31Earnings Summary - TradingView
Compugen (CGEN) Reports Q4 Loss, Misses Revenue Estimates - Yahoo Finance
Compugen: Q4 Earnings Snapshot - CTPost
Compugen earnings missed by $0.09, revenue fell short of estimates - Investing.com South Africa
Compugen Reports 2024 Financial Results and Clinical Progress - TipRanks
Compugen: Q4 Earnings Snapshot -March 04, 2025 at 07:23 am EST - Marketscreener.com
Compugen Reports Fourth Quarter and Full Year 2024 Results -March 04, 2025 at 07:13 am EST - Marketscreener.com
Compugen reports Q4 EPS (7c) vs. 11c last year - TipRanks
Earnings Flash (CGEN) COMPUGEN LTD. Posts Q4 Loss $-0.07 Per Share -March 04, 2025 at 07:08 am EST - Marketscreener.com
Earnings Flash (CW9) COMPUGEN LTD. Posts Q4 Revenue $1.5M - Marketscreener.com
Earnings Flash (CGEN) COMPUGEN LTD. Posts Q4 Revenue $1.5M -March 04, 2025 at 07:09 am EST - Marketscreener.com
How Compugen's Cancer Immunotherapy Pipeline Is Advancing While Extending Cash Runway to 2027 - StockTitan
Cancer Immunotherapy Pioneer Compugen to Share Insights at Major Healthcare Conference - StockTitan
Compugen to Participate in a Fireside Chat at the 2025 Leerink Partners Global Healthcare Conference - Yahoo Finance
Compugen (CGEN) Projected to Post Quarterly Earnings on Tuesday - Defense World
Compugen Ltd expected to post earnings of 7 cents a shareEarnings Preview - TradingView
Compugen (CGEN) Expected to Announce Earnings on Tuesday - MarketBeat
Improved Revenues Required Before Compugen Ltd. (NASDAQ:CGEN) Shares Find Their Feet - Simply Wall St
How Compugen's AI Platform Partnership Could Revolutionize Cancer Immunotherapy Discovery - StockTitan
Compugen Ltd. Enhances its AI/ML Predictive Computational Discovery Platform, Unigen?? with Ultima Genomics' Single Cell Genomics Sequencing Technology - Marketscreener.com
Compugen Ltd. Sets Date for Q4 2024 Financial Results Announcement - TipRanks
Earnings Alert: Compugen Sets Date for Critical Year-End Financial Report & Strategic Update - StockTitan
Compugen: Immuno-Oncology Innovator Poised For A Comeback (NASDAQ:CGEN) - Seeking Alpha
Compugen (NASDAQ:CGEN) Shares Cross Above 200-Day Moving Average – Time to Sell? - Defense World
Compugen Announces Significant Share Price Increase - TipRanks
Finanzdaten der Compugen Ltd-Aktie (CGEN)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):